Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.31 CHF | +0.39% |
|
-1.66% | +4.05% |
| Feb. 09 | This time it's for real |  |
| Feb. 07 | Abivax appoints new head of quality | CF |
| Sales 2024 * | 48.21B 42.16B | Sales 2025 * | 50.28B 43.97B | Capitalization | 206B 180B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.1B 8.84B | Net income 2025 * | 11.4B 9.97B | EV / Sales 2024 * | 4.52 x |
| Net Debt 2024 * | 11.59B 10.13B | Net Debt 2025 * | 10.37B 9.07B | EV / Sales 2025 * | 4.31 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
16.7
x | Employees | 76,057 |
| Yield 2024 * |
3.72% | Yield 2025 * |
3.85% | Free-Float | 86.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More press releases
More news
| 1 day | +0.39% | ||
| 1 week | -1.66% | ||
| Current month | -1.22% | ||
| 1 month | -3.11% | ||
| 3 months | +4.76% | ||
| 6 months | -2.60% | ||
| Current year | +4.05% |
1 week
87.97
91.15
1 month
87.6894.52
Current year
86.5094.52
1 year
73.7494.77
3 years
72.8494.77
5 years
65.0996.38
10 years
65.09103.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04-12-31 | |
| Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
| Chairman | 68 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | ||
| 5.57% | 19 M€ | +2.97% | - | |
| 4.12% | 88 M€ | +10.37% | - | |
| 3.79% | 2 M€ | -25.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 88.31 | +0.39% | 2,930,012 |
| 24-02-08 | 87.97 | -3.04% | 3,278,855 |
| 24-02-07 | 90.73 | +0.71% | 2,819,723 |
| 24-02-06 | 90.09 | -0.30% | 2,691,800 |
| 24-02-05 | 90.36 | +0.62% | 3,380,878 |
Delayed Quote Swiss Exchange, February 09, 2024 at 11:30 am EST
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (18.3%; Sandoz).
Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
Sector
Pharmaceuticals
Calendar
2024-03-04
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
101
USD
Average target price
109.3
USD
Spread / Average Target
+8.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.05% | 206 B $ | |
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| -8.02% | 207 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ | |
| -3.63% | 117 B $ |
